Related Experiment Video

Updated: May 23, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment

Sook Ryun Park1, Alice Chen

  • 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Room 3A44, Bethesda, MD 20892, USA.

Hematology/Oncology Clinics of North America
|April 24, 2012
PubMed

Insights

Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show promise for treating BRCA-mutant cancers. These inhibitors are being investigated for various sporadic cancers due to DNA repair defects, enhancing treatment efficacy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors represent a significant advancement in cancer therapy.
  • Synthetic lethality strategies, particularly targeting BRCA-mutant cancers, have shown clinical success.
  • Defects in DNA repair pathways are common in sporadic cancers, suggesting broader therapeutic potential for PARP inhibitors.

Purpose of the Study:

  • To review DNA repair mechanisms and the role of PARP as a therapeutic target.
  • To summarize current clinical trials involving PARP inhibitors.
  • To discuss predictive biomarkers for PARP inhibitor efficacy.

Main Methods:

  • Literature review of DNA repair mechanisms.
  • Analysis of current clinical trial data for PARP inhibitors.
  • Examination of predictive biomarkers in cancer treatment.

Main Results:

  • PARP inhibitors are effective in BRCA-mutant cancers via synthetic lethality.
  • PARP inhibitors are being explored in combination with DNA-damaging agents for sporadic cancers.
  • Biomarkers are crucial for identifying patient populations likely to respond to PARP inhibitors.

Conclusions:

  • PARP inhibitors are a key therapeutic strategy for DNA repair-deficient cancers.
  • Ongoing research is expanding the application of PARP inhibitors to a wider range of malignancies.
  • Personalized medicine approaches using predictive biomarkers will optimize PARP inhibitor therapy.

More Related Videos

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)

Published on: January 20, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...